Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study.

ABSTRACT:

Objective

To evaluate the clinical and microbiological efficacy and safety of three doses of 3 g fosfomycin tromethamine administered orally to treat lower urinary tract infections.

Design and participants

This prospective, uncontrolled, open-label study was conducted in 12 medical centres in China, between January and December 2011. According to the diagnosis criteria of Chinese Guidelines on Urological Infections, patients (18-70 years) with acute uncomplicated cystitis, recurrent lower urinary tract infection or complicated lower urinary tract infection received three doses of 3 g fosfomycin tromethamine orally, at days 1, 3 and 5.

Primary and secondary outcome measures

Efficacy endpoints (clinical efficacy, microbiological efficacy and overall efficacy) were evalu

SUBMITTER: Qiao LD 

PROVIDER: S-EPMC3855495 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature